Industry & Policy News

[Fierce Pharma] The FDA has cleared Bristol Myers’ repotrectinib, to be branded as Augtyro, to treat non-small cell lung cancer patients whose tumors have ROS1 oncogenic fusions.

[The University of Massachusetts Lowell] A UMass Lowell scientist is hoping to improve the quality of life for those with diabetes using innovative biomaterials and engineered cells and tissues, including an insulin-producing, bioengineered pancreas-like tissue.

[Fierce Pharma] Vertex and CRISPR Therapeutics have scored authorization in the UK for their exa-cel gene therapy to treat patients with severe forms of sickle cell and transfusion-dependent beta thalassemia, two genetic disorders of the blood.

[Singapore-MIT Alliance for Research and Technology (SMART)] Researchers from SMART, MIT’s research enterprise in Singapore have developed a groundbreaking technology capable of extracting MSCs directly from pure bone marrow without dilution.

[University of Alberta] A renowned expert is joining the University of Alberta to research a critical underlying defect in all types of diabetes, with the goal of improving treatment, thanks to support through the Canada Excellence Research Chairs program.

[STAT News] Academia is in the midst of an unprecedented exodus of life science researchers, many of whom are leaving for lucrative jobs in the private sector.